Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852222 · ClinicalTrials.gov registry record · Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 3 study of Leukemia, Myeloid, Acute, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06852222 is a Phase 3 study of Leukemia, Myeloid, Acute that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 600 participants, above the 96-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (525% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06852222, a Phase 3 study of Leukemia, Myeloid, Acute, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bleximenib
- DRUG Venetoclax (VEN)
- DRUG Azacitidine (AZA)
Study Locations (20)
Florida
- Memorial Regional Hospital - Hollywood
- Jupiter Research - Jupiter
- Orlando Health Cancer Institute - Orlando
- Moffit Cancer center - Tampa
- Cleveland Clinic Florida - Weston
Kentucky
- University of Kentucky Markey Cancer Center - Lexington
- UofL Health Brown Cancer Center - Louisville
- Norton Cancer Institute - Louisville
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- New York Presbyterian - Weill Cornell - New York
- University of Rochester Medical Center - Rochester
Arizona
- Cancer Treatment Center of America Phoenix - Goodyear
Arkansas
- University of Arkansas at Little Rock - Little Rock
California
- City of Hope - Duarte
Illinois
- University of Chicago Medicine - Chicago
Louisiana
- Mary Bird Perkins Cancer Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06852222
The ClinicalTrials.gov registry entry for NCT06852222 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (525% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06852222 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Kentucky, New York.
Frequently Asked Questions
What is clinical trial NCT06852222 about?
NCT06852222 is a clinical study titled "A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)". The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
What is the current status of trial NCT06852222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-06-04. Estimated completion is 2029-08-15.
What conditions does trial NCT06852222 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT06852222?
The interventions under investigation include: Placebo (DRUG), Bleximenib (DRUG), Venetoclax (VEN) (DRUG), Azacitidine (AZA) (DRUG).
Who is sponsoring clinical trial NCT06852222?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852222 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
RECRUITING · Phase 2
-
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.